(Q37552052)

English

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation

scientific article published on 20 September 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Epstein–Barr virus

0 references

stem cell transplantation

1 reference

based on heuristic

inferred from title

object named as

Mikael Sundin

3

0 references

object named as

Jonas Mattsson

10

0 references

object named as

Markus Maeurer

5

0 references

8

object named as

Per Ljungman

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

author name string

Michael Uhlin

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Helena Wikell

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Ola Blennow

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Olle Ringden

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Jacek Winiarski

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Mats Remberger

9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

publication date

20 September 2013

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

99

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

346-352

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Organization of immunological memory by bone marrow stroma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

How I treat EBV lymphoproliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Stromal niches, plasma cell differentiation and survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Post-transplant lymphoproliferative disorder: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Identifying the patient at risk for post-transplant lymphoproliferative disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

23 August 2017

Immune regulatory function of B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

6 September 2017

High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

6 September 2017

Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

14 September 2017

Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

25 June 2018

Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

25 June 2018

Rapid salvage treatment with virus-specific T cells for therapy-resistant disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912966

1 September 2018

Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretransplantation assessment of the risk of lymphoproliferative disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/24056821

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2013.087338

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37552052&oldid=2215132604"